OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
OKYO Pharma Limited (AIM:OKYO) U.S. FDA Clearance of IND Application for OK-101
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (AIM:OKYO) OKYO to Participate at Biotech Showcase
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease
OKYO Pharma LTD (AIM:OKYO) Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to
OKYO Pharma LTD (AIM: OKYO) announces issuance of U.S. Patent No. 11,254,720
Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.
OKYO Pharma Limited (OKYO.L) IND filing Q3 2022 and Phase 2 initiation Q4 2022
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients
OKYO Pharma LTD (OKYO.L) Announces final audited results for the year ended 31 March 2021
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
OKYO Pharma Limited (OKYO.L) Regulatory Development of OK-101 for Dry Eye Indications
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
OKYO Pharma Limited (OKYO.L) Publication of a Prospectus
Prospectus Publication Announcement